REG - Hikma Pharmaceutical - Publication of Offering Circular

Hikma PharmaceuticalsAnnouncement

07/07/2025 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250707:nRSG9905Pa&default-theme=true

RNS Number : 9905P  Hikma Pharmaceuticals Plc  07 July 2025

Hikma Finance USA LLC

Publication of Offering Circular

 

7 July 2025

Hikma Finance USA LLC (the "Issuer") announces today that it has published an
offering circular dated 7 July 2025 (the "Offering Circular") in connection
with the issuance of US$500,000,000 5.125 per cent. Guaranteed Notes due 2030
(the "Notes") guaranteed by Hikma Pharmaceuticals PLC.

The Notes are expected to be admitted to trading on the International
Securities Market of the London Stock Exchange on or about 9 July 2025.

The Offering Circular is available for viewing.

To view the Offering Circular please paste the following URL into the address
bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/9905P_1-2025-7-7.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/9905P_1-2025-7-7.pdf)

 

Enquiries and Investor Relations

 Susan Ringdal

 EVP, Strategic Planning and Global Affairs

 +44 (0) 20 7399 2760 / +44 7776 477050

 

LEI: 213800BU7YH2WTM1QL87

Regulated Information Classification: Additional regulated information
required to be disclosed under the laws of a Member State

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Offering Circular may be
addressed to and/or targeted at persons who are residents of particular
countries (specified in the Offering Circular) only and is not intended for
use and should not be relied upon by any person outside these countries and/or
to whom the offer contained in the Offering Circular is not addressed. Prior
to relying on the information contained in the Offering Circular, you must
ascertain from the Offering Circular whether or not you are one of the
intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above
requirement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CIRPKOBDFBKKNOK